麻豆传媒

Cardiovascular mortality in the U.S. , but the pace of decline slowed in the last decade, death certificates suggest. (European Journal of Preventive Cardiology)

The evidence favors continuing SGLT-2 inhibitor therapy for heart failure even , according to a pooled analysis of DAPA-HF and DELIVER. (Journal of the American College of Cardiology)

Percutaneous coronary intervention (PCI) was more successful and associated with less stent thrombosis when (OCT) as opposed to traditional angiography, according to the ILUMIEN IV group. (New England Journal of Medicine)

In fact, with routine OCT guidance for PCI on complex coronary artery bifurcation lesions. (New England Journal of Medicine)

Unsubstantiated heart health claims were often found on the labels of on the market. (JAMA Cardiology)

Another PCSK9 inhibitor emerges, as lerodalcibep, cut LDL cholesterol in heterozygous familial hypercholesterolemia in a phase III trial. (European Heart Journal)

ORION-8 showed that twice-yearly inclisiran (Leqvio) injections continued to confer , Novartis said.

A first-in-human study finds reduces lipoprotein(a) levels without safety or tolerability issues. (JAMA)

Sports cardiologists give context to the reported finding of a that led to Bronny James' cardiac arrest. (Yahoo Sports)

In the observational ATHENS study, people with non-valvular atrial fibrillation who reportedly had more stroke, systemic embolism, and major bleeding events than those staying on apixaban, Bristol Myers Squibb-Pfizer said.

People in their 80s who underwent transcatheter edge-to-edge mitral valve repair appeared to have in the MitraSwiss registry. (JACC: Cardiovascular Interventions)

The efficacy of mavacamten (Camzyos) was with symptomatic obstructive hypertrophic cardiomyopathy, the EXPLORER-CN trial showed. (JAMA Cardiology)

The antioxidant was a flop for infarct size reduction in ST-segment elevation myocardial infarction. (JACC: Basic to Translational Science)

Investigational gene therapy continued to show promise for refractory angina, most recently with 6-month efficacy data from the EXACT trial, XyloCor Therapeutics announced.

A new Lancet Commission report urged a multidisciplinary strategy to . (Lancet)

Comment